Navigation Links
Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Date:9/10/2007

ers are attached to therapeutic agents, and it is applicable to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs.

Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, and manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar is also developing its own product candidates by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of the company's PEGylation technology platform and NKTR-118. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) clinical trials for NKTR-118 are long, expensive and uncertain processes, (ii) because the NKTR-118 product development program is in the early phases of clinical development, the risk of failure is high and can occur at any stage of development, (iii) the company may fail to obtain regulatory approval of NKTR-118, (iv) potential competition from approved drugs or drugs under development that may be safe and effective for the same indication as that targeted by NKTR-118, and (v) the company's patent applications for NKTR-118 may fail to issue; patents that have issued may not be enforceable; or unanticipated intellectual property licenses from third parties may be required in the futur
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
5. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
6. Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS
7. Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS
8. Sonic Foundry reports first cash-positive quarter
9. Theres a surprising, and positive, side to the offshore jobs debate
10. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
11. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 ... and medical information products and services, today announced the ... According to the 2014 Journal Citation Reports® (JCR) published ... Impact Factors increase from 2013 to 2014, ahead of ... occupied the top rank in 62 subject categories, up ...
(Date:6/26/2015)... ... June 26, 2015 , ... Charm Sciences, Inc. is ... and Stockyards Administration (GIPSA) awarded a five year contract to Charm Sciences to ... Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative test extracts DON from samples ...
(Date:6/26/2015)... , June 23, 2015 ... the addition of the "Global Cancer Biosimilars ... Market introduction of cancer biosimilar is ... commercialization potential. Chemotherapeutic drugs have dominated the cancer ... have been introduced in past few years. They ...
(Date:6/25/2015)... 25, 2015 Last June, a dedicated global team ... virus using large-scale genome sequencing. Their research, which was written ... the journal Cell (Park 2015) , reveals ... seven months of the recent Ebola outbreak. Today ... data, workflows, and full edit history of the paper ...
Breaking Biology Technology:Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3Open Science Takes Major Leap Forward 2
... TNGN ), a leader in regenerative medicine, today ... on Wednesday, October 27, 2010 in New York, New York. ... product development portfolio and upcoming corporate milestones, and will expand ... The live webcast of the event will be available ...
... Calif., Oct. 12 With more than 200 ... Workshop, Microsoft Research showcases two technologies that facilitate ... a MODISAzure-based environmental service. (Logo: ... Programmers and developers in bioscience now ...
... The Ontario Institute for Cancer Research (OICR) today announced ... Inc., an Ontario company that is developing a software ... detailed disease and treatment data without compromising individual privacy. ... Assessment Tool (PARAT), is currently being used by hospitals ...
Cached Biology Technology:Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010 2Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 2Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 3Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 4OICR Makes Equity Investment in Medical Information Company 2
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... , SANTA ANA, Calif. and ... Microsystems, Inc., d.b.a. Identive Group (Nasdaq: INVE ; Frankfurt ... for the security, identification and RFID industries, today announced that ... three new executives in line with the announced reorganization of ...
... 2010 The Translational Genomics Research Institute (TGen) today ... agreement with the Van Andel Research Institute (VARI) that ... TGen expects the agreement to create a ... and treatments for patient benefit. ...
... Medicine believe they may have discovered how the hormone ... findings will be presented at the Annual Scientific Meeting ... by Errol Norwitz, M.D., professor in the Department of ... Preterm birthdelivery prior to 37 weeks gestationhas become increasingly ...
Cached Biology News:Identive Group Expands Executive Management Team 2Identive Group Expands Executive Management Team 3TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3
...
... Antigen peptide transporter ... TAP2) (Peptide transporter PSF2) ... (PSF-2) (Peptide transporter involved ... [Source:Uniprot/SWISSPROT;Acc:Q03519] ...
... Recognizes Nabeta2. The epitope specific ... in any other known proteins.,SPECIES ... to work on human because ... conserved (17/19 residues). Reactivity with ...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Biology Products: